Leerink Partnrs Analysts Raise Earnings Estimates for enGene

enGene Holdings Inc. (NASDAQ:ENGN) – Stock analysts at Leerink Partnrs upped their FY2026 earnings estimates for shares of enGene in a note issued to investors on Wednesday, January 22nd. Leerink Partnrs analyst M. Foroohar now anticipates that the company will post earnings of ($1.85) per share for the year, up from their prior forecast of ($1.89). The consensus estimate for enGene’s current full-year earnings is ($1.57) per share. Leerink Partnrs also issued estimates for enGene’s FY2027 earnings at ($1.74) EPS and FY2028 earnings at ($0.45) EPS.

A number of other equities research analysts have also issued reports on the stock. JMP Securities restated a “market outperform” rating and set a $18.00 price target on shares of enGene in a report on Monday, December 23rd. HC Wainwright assumed coverage on shares of enGene in a report on Monday, December 23rd. They set a “buy” rating and a $25.00 price target on the stock. Raymond James assumed coverage on shares of enGene in a research note on Wednesday, November 27th. They issued an “outperform” rating and a $23.00 price objective on the stock. Finally, Citizens Jmp upgraded shares of enGene to a “strong-buy” rating in a research note on Monday, November 18th. Ten investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $29.78.

enGene Stock Down 1.8 %

ENGN stock opened at $7.16 on Friday. enGene has a 52-week low of $4.42 and a 52-week high of $18.40. The company’s 50 day simple moving average is $7.37 and its 200-day simple moving average is $7.54. The company has a debt-to-equity ratio of 0.08, a current ratio of 16.87 and a quick ratio of 16.87. The firm has a market capitalization of $316.62 million, a P/E ratio of -12.34 and a beta of -0.65.

enGene (NASDAQ:ENGN) last released its quarterly earnings results on Thursday, December 19th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.06.

Institutional Trading of enGene

Several large investors have recently added to or reduced their stakes in ENGN. Wolverine Asset Management LLC bought a new stake in enGene in the third quarter worth approximately $37,000. Point72 Asset Management L.P. grew its position in enGene by 1,410.3% in the third quarter. Point72 Asset Management L.P. now owns 663,000 shares of the company’s stock worth $4,376,000 after acquiring an additional 619,100 shares in the last quarter. Finally, Franklin Resources Inc. grew its position in enGene by 48.7% in the third quarter. Franklin Resources Inc. now owns 1,189,952 shares of the company’s stock worth $7,854,000 after acquiring an additional 389,918 shares in the last quarter. 64.16% of the stock is owned by institutional investors.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.